🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to BioJapan — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds
About this event
BioJapan (Regenerative Medicine JAPAN / healthTECH JAPAN) — Global Bio-Industry Partnering Event Analysis
1) Event basics (real details from the official website)
- Event name: BioJapan (concurrent: Regenerative Medicine JAPAN, healthTECH JAPAN)
- Dates: Oct. 7–9, 2026 (Wed.–Fri.)
- Venue: PACIFICO Yokohama
- City & country: Yokohama, Japan
- Event positioning: “The Premier Bio-Industry Partnering Event in Asia”
- Scale indicator (official “previous show/visitor count” snapshot): The website shares visitor count “including concurrent events” as a preliminary result.
2) Who attends (BUYERS / ATTENDEES)
BioJapan is structured as a partnering-first bio-industry marketplace rather than a purely product-focused exhibition. That changes who matters most: the highest-value “buyers” for attendee/buyer lists are typically organizations and decision-makers that can evaluate partnerships, licensing, collaborations, sponsored R&D, distribution, and co-development.
Main attendee / buyer categories (what we should target for lead quality):
- Biopharma and specialty pharma partnering teams (business development, alliance management, licensing)
- Regenerative medicine stakeholders (cell therapy, tissue engineering, advanced therapies, translational medicine teams)
- Health technology decision-makers (digital health, diagnostics, connected healthcare, healthtech product strategy)
- Research & innovation organizations (life science research institutes, translational research groups, innovation offices)
- R&D and technology providers (platform technologies, manufacturing technology, lab/clinical services)
- Investment and ecosystem connectors (venture/strategic investors, accelerators, industry associations that matchmake partnerships)
- Clinical and regulatory-linked stakeholders (clinical operations leadership, regulatory strategy, quality/compliance decision-makers)
- Industry associations and organizing ecosystem contributors (policy/industry collaboration advocates; useful for network-wide visibility)
In practical list-building terms, the “best buyers” are usually not general attendees. They are the people whose job responsibilities map directly to partnering outcomes: finding targets, screening technologies, entering collaboration agreements, and making go/no-go investment decisions.
3) Where the show is happening + attendee geographic origin
Show location: PACIFICO Yokohama, Yokohama, Japan.
Attendee geographic origin: The official website positions BioJapan as a premier bio-industry partnering event in Asia, which typically indicates a cross-regional attendance footprint across Asia and strong international participation from global life-science ecosystems. However, the provided official text does not list a precise breakdown by country/region for visitors.
How we would geo-target (recommended approach for deep buyer list research):
- Primary: Japan-based life science, regenerative medicine, and healthtech organizations (partnering-oriented teams)
- Secondary (high-likelihood): Asia-Pacific companies (Japan, Korea, Taiwan, Singapore, China, Hong Kong)
- Global long-tail: North America and Europe tech/biopharma with Japan/APAC partnership strategies
If we receive your client’s target geography priorities, we can tighten this further into a buyer-matching plan by company HQ region and Japan presence.
4) Audience reach (Local / National / Global)
Based on the official description (“Premier Bio-Industry Partnering Event in Asia”), BioJapan should be treated as a regional-to-global draw, with a strong concentration in Japan and meaningful cross-border participation due to the partnering format.
Best classification for reach planning: National (Japan) + Asia-wide + international visibility.
5) Job profiles, industries & event type
Event type
- Bio-industry partnering / matchmaking
- Regenerative medicine industry platform (via “Regenerative Medicine JAPAN” concurrent track)
- Health technology industry platform (via “healthTECH JAPAN” concurrent track)
- Exhibition + seminars + partnering (the website navigation indicates these three pillars)
Best job profiles to target (buyer-side roles)
- Business Development Director / VP (strategic partnerships)
- Alliance Manager / Partnering Manager
- Licensing & BD Manager (IP, technology acquisition)
- Head of Corporate Development (M&A / strategic alliances)
- Regenerative Medicine Program Lead
- Clinical Development / Clinical Operations Leadership
- Translational Research / R&D Strategy Lead
- Regulatory Affairs Strategy Lead
- Technology Scouting / Open Innovation Manager
- Healthtech Product Strategy Director (platform/product partnerships)
- Innovation Office / Ecosystem Partnerships Manager
Best industry fit (aligned to Apollo-style industry choices)
We can map BioJapan’s themes into the following industry filters commonly used for buyer targeting:
- Pharmaceuticals
- Biotechnology
- Medical Devices
- Hospital & Health Care
- Health, Wellness & Fitness (only when client is wellness/digital interventions)
- Research
- Information Technology & Services (especially for healthtech software/platform partnerships)
- Internet (when healthtech includes digital platforms)
- Professional Training & Coaching (only if the client sells training/certification for life science roles)
- Renewables & Environment (usually not core, unless it’s bio-manufacturing sustainability tech)
6) Estimated attendance (expected total footfall)
The official site provides a “visitor count (preliminary result)” for a prior show, including concurrent events:
- Oct. 8th: 9,004 visitors
- Oct. 9th: 7,671 visitors
- Oct. 10th: 5,492 visitors
- Total: 22,167 visitors
For planning purposes for 2026: we should treat this as a benchmark and build scenarios (conservative/base/aggressive) once we confirm whether the 2026 layout and concurrent themes expand or contract. Since the exact 2026 visitor count is not provided in the supplied text, we will not invent a 2026 footfall number.
7) Key focus areas & buyer engagement
Because BioJapan is positioned as a bio-industry partnering event, the engagement and the “why meet” narrative will consistently revolve around deal-making and collaboration.
Key focus areas we should use for buyer mapping:
- Partner discovery: identifying companies and research entities to collaborate with
- Regenerative medicine translation: moving therapies from research into clinical/market pathways
- Healthtech commercialization: adoption strategy, evidence generation, and ecosystem partnerships
- Technology access: licensing, platform integration, co-development
- Manufacturing & enabling tech: advanced manufacturing, quality systems, scalability
- Clinical and regulatory readiness: compliance, documentation, and trial coordination capabilities
- Strategic and corporate development outcomes: alliances that match long-term portfolios
Buyer engagement angle we recommend using in outreach messaging:
- “We support your partnering outreach for the BioJapan ecosystem—so your team can identify the right alliance targets efficiently.”
- “We help you surface decision-makers across regenerative medicine and healthtech aligned to partnership and evaluation needs.”
8) Client-product fit note (we need your client website to finalize the best buyers)
We can absolutely recommend the best buyer segments, but to do it accurately we must align the event buyer types to your client’s exact offering. The official text confirms the event verticals (bio/regen medicine/healthtech), but buyer fit depends on whether your client sells: technologies, services, platform software, clinical solutions, devices, or investment/acceleration.
Please share:
- Your client website URL (the one we must review)
- What the client sells (1–2 sentences)
- Top target geographies (Japan only vs APAC/global)
- Whether the client sells to pharma/biotech, hospitals, healthtech software buyers, or research institutes
What we will do immediately after you share the website:
- Extract the product category (e.g., cell therapy enabling tech, healthtech platform, diagnostics, manufacturing tech, clinical services)
- Map the product to the most relevant event track: BioJapan regenerative medicine vs healthTECH emphasis
- Generate a “best buyer fit” list by role titles (BD, partnering, licensing, innovation, clinical strategy, regulatory strategy, product strategy)
- Produce an Apollo-style industry filter shortlist matched to your client’s category
Provisional best-fit assumption (if the client is broadly in bio/healthtech):
- Highest priority buyers: Business Development / Alliance / Licensing leadership
- Strong priority buyers: Innovation / Technology Scouting managers
- High priority for regenerative medicine products: Regenerative medicine program leads + clinical/translational decision-makers
- High priority for healthtech products: Product strategy + partnerships + digital health evidence/clinical stakeholders
9) Sample buyer company names (BUYERS ONLY) + websites
Below is a buyer-oriented sample list for BioJapan-style partnering. Because the provided official text does not include exhibitor/partner rosters, we cannot prove these exact organizations are attending. We therefore label this as a targeting sample to help research start quickly. Once we confirm your client website, we will refine this list toward the companies with the highest match to your product category and typical partnering behavior.
| Priority | Company | Website | Best Title to Target | Why This is a Good Buyer Fit |
|---|---|---|---|---|
| 1 | Takeda Pharmaceutical Company Limited | https://www.takeda.com | Head of Business Development / Alliance Management | Strong fit for partnering and strategic alliances across pharma innovation, including regenerative medicine and healthtech-adjacent platforms. |
| 2 | Chugai Pharmaceutical Co., Ltd. | https://www.chugai-pharm.co.jp | BD & Licensing Director / Alliance Manager | High likelihood of evaluating external innovations; role scope aligns to partnership identification and deal orchestration. |
| 3 | Meiji Seika Pharma Co., Ltd. | https://www.meiji.com | Open Innovation / Technology Scouting Manager | Typical buyer profile for scouting technologies and forming collaborations relevant to advanced therapeutics and enabling platforms. |
| 4 | Asahi Kasei (Life Science / Biopharma activities) | https://www.asahi-kasei.com | Corporate Development / Strategic Partnerships Lead | Good match for partnering-focused strategies involving life science innovation and ecosystem collaboration. |
| 5 | Terumo Corporation | https://www.terumo.com | Strategic Partnerships Manager / BD Director | Strong fit if the client’s product touches medical technology and advanced therapeutic workflows, where partnerships accelerate adoption. |
| 6 | Sysmex Corporation | https://www.sysmex.com | Healthtech Partnerships Director / BD Lead | Ideal for healthtech and diagnostics-linked buyers evaluating co-development and integration opportunities. |
| 7 | HOYA Corporation | https://www.hoya.com | BD / Alliance Manager (Life Science & Medtech) | Potential buyer fit when the client offers enabling tech (imaging, instrumentation, life-science components) for medical innovation. |
| 8 | Fujifilm Corporation | https://www.fujifilm.com | Open Innovation Director / Strategic Alliance Manager | High probability of technology evaluation and collaboration, especially across healthcare platforms and innovation ecosystems. |
| 9 | Sumitomo Pharma Co., Ltd. | https://www.sumitomopharma.com | Business Development Director / Licensing & Alliances | Partnering-oriented roles commonly review external pipelines and enabling technologies aligned to therapeutic strategy. |
| 10 | Nippon Shinyaku Co., Ltd. | https://www.nippon-shinyaku.co.jp | Alliance & BD Manager | Solid fit for identifying collaboration targets and evaluating technology relevance for future portfolio expansion. |
| 11 | Takara Bio Inc. | https://www.takarabio.com | Partnerships / Business Development Manager | Strong alignment with life science reagent & platform ecosystems that collaborate with research and translational pipelines. |
| 12 | Lonza (Japan operations / regional partnering) | https://www.lonza.com | Strategic Partnerships / BD Director (CDMO or enabling services) | Good fit if the client provides manufacturing, process development, or enabling services that CDMO-like organizations partner on. |
| 13 | Samsung Biologics (Japan-linked partnering teams) | https://www.samsungbiologics.com | Business Development Director / Alliance Manager | Potential buyer fit for partnering around development and manufacturing capacity, where collaborations can accelerate scale-up. |
| 14 | Agilent Technologies (health/life science) | https://www.agilent.com | Strategic Partnerships Manager / BD Director | Relevant if the client’s solutions integrate into research workflows, translational environments, or clinical enabling processes. |
| 15 | Illumina (health/life sciences) | https://www.illumina.com | Partnerships Director / Business Development Lead | Good match when the client offers bio-enabling technologies (data, tools, platforms) that drive collaborative translation. |
| 16 | Osaka University (innovation and translational units) | https://www.osaka-u.ac.jp | Technology Transfer / Open Innovation Director | Research institutions are major sources of technologies; partnering decision-makers align directly with BioJapan-style collaboration. |
| 17 | RIKEN (Japan research institute) | https://www.riken.jp | Innovation / Partnership Development Lead | Strong fit if the client provides translational tools, collaboration pathways, or enabling tech for advanced life-science programs. |
| 18 | Meiji University / Meiji Seika-linked ecosystem partners (innovation arms) | https://www.meiji.ac.jp | Research Collaboration / Innovation Office Manager | Useful for mapping research collaboration needs toward translational and partnering outcomes. |
Top 5 buyer-fit sample targets to start with (for rapid outreach testing): Takeda, Chugai Pharmaceutical, Meiji Seika Pharma, Asahi Kasei, Terumo. These represent high-probability partnering functions across pharma/medtech that align with event matchmaking intent.
Next step (so we can truly “best buyer fit” this for your client)
Please send the client website URL. After we review it, we will: (1) identify the closest event track emphasis (BioJapan / regenerative medicine / healthTECH), (2) select the most appropriate job titles and industries from the Apollo-style industry list, and (3) deliver a refined buyer list strategy tailored to your client’s specific offering.
Data sheet
BioJapan – Event Attendee & Buyer Profile Analysis
Event Date: 2026-10-07 to 2026-10-09
Location: PACIFICO Yokohama, Yokohama, Japan
Event Status: Upcoming
Research Date: 2026-06-30
Event Overview
| Event Name | BioJapan / Regenerative Medicine JAPAN / healthTECH JAPAN |
| Event Date | 2026-10-07 to 2026-10-09 |
| Event Status | Upcoming |
| Venue | PACIFICO Yokohama |
| City | Yokohama |
| State / Region | Kanagawa Prefecture |
| Country | Japan |
| Organizer | BioJapan Organizing Committee / Japan Bioindustry Association (JBA) / JTB Communication Design, Inc. / Forum for Innovative Regenerative Medicine (FIRM) |
| Official Event Website | jcd-expo.jp/en/ |
| Event Type | Bio-industry exhibition, partnering event, seminar program, and business matchmaking platform |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research; IT & Technology; Wellness, Health & Fitness; Business Services |
| Audience Reach | Global |
| Estimated Attendance / Expected Footfall | Attendance figure not publicly confirmed by the organizer. Historical 2025 visitor count was 22,167 (including concurrent events). |
| Attendance Data Reliability | Medium: 2025 visitor count published by organizer; 2026 attendance not yet confirmed. |
| Main Purpose of Event | To connect bio-industry, regenerative medicine, and health-tech stakeholders for partnering, sourcing, commercialization, collaboration, research exchange, and business development. |
About the Event
BioJapan is presented as “The Premier Bio-Industry Partnering Event in Asia” and combines exhibition, partnering, and seminar components with a strong emphasis on business matchmaking. The official site positions the 2026 edition as the 40th anniversary event, which reinforces its status as a long-running, high-credibility platform for the life sciences ecosystem.
The event is especially relevant for organizations seeking partnerships in biotechnology, regenerative medicine, and digital health / health-tech. Its attendee mix typically supports commercial development, sourcing, research collaboration, licensing, technology transfer, and strategic procurement conversations, making it highly useful for B2B lead generation and buyer profiling in the medical and research markets.
1. Who Attends: Buyers / Attendees
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| R&D and Innovation Leaders | Pharma, biotech, diagnostics, regenerative medicine, health-tech firms | Evaluate platforms, collaborators, tools, and technologies | Very high for licensing, R&D tools, assay platforms, AI, and translational solutions |
| Business Development / Alliance Teams | Life science companies, universities, research institutes, startups | Seek partnering, co-development, licensing, and channel relationships | Primary audience for meeting-booking and partnering platforms |
| Procurement and Sourcing Teams | Pharma manufacturers, hospital systems, research labs, device makers | Select suppliers for lab equipment, reagents, software, and services | Strong fit for suppliers with validated products, regulatory support, and service contracts |
| Regulatory / Quality Affairs | Pharma, medtech, cell therapy, diagnostics, CROs | Influence vendor qualification, compliance, and product acceptance | Important for compliance-heavy service and technology vendors |
| Clinical Development / Translational Medicine | Biopharma, hospitals, translational research centers | Assess clinical research support, trial tools, and patient-centric solutions | Useful for CROs, trial software, biomarker and sample-handling vendors |
| Academic / Research Institute Leaders | Universities, national labs, public research institutes | Source research collaboration, grants, instrumentation, and partnerships | Relevant for instrumentation, software, publishing, and grant-support providers |
| Investors / Corporate Venture Teams | VCs, CVCs, accelerators, strategic investors | Identify startups and platform technologies for investment or acquisition | High value for startups seeking funding and commercialization partners |
| Government and Public-Sector Representatives | Science agencies, health ministries, innovation offices, public research bodies | Support policy, grants, innovation programs, and public procurement | Relevant for policy, digital health, biotech infrastructure, and public research vendors |
| Media / Industry Analysts | Life science media, trade publications, analyst firms | Amplify market visibility and announcements | Useful for launches, PR, and thought leadership |
2. Event Location and Attendee Geographic Origin
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| Host city: Yokohama | Local life science companies, universities, hospitals, and regional suppliers | Medium | Direct access via PACIFICO Yokohama and the greater Tokyo Bay market |
| Host region: Kanagawa / Greater Tokyo | Pharma HQs, biotech startups, research institutes, venture firms | High | Japan’s largest concentration of corporate and research decision-makers is within easy travel distance |
| National reach: Japan | Nationwide pharma, biotech, medtech, universities, public institutes, and healthcare organizations | Very High | The organizer’s national associations support broad domestic attendance |
| International reach: Asia, North America, Europe | Global biotech, medtech, CRO, licensing, and investment stakeholders | High | The event is explicitly positioned as Asia’s premier bio-industry partnering platform |
| Key business hubs | Tokyo, Osaka, Kyoto, Kobe, Tsukuba, Nagoya, Fukuoka, Seoul, Taipei, Singapore, Boston, San Diego | High | These hubs are strong sources of partnering, research, and commercialization traffic |
3. Audience Reach
| Reach Level | Assessment | Explanation |
|---|---|---|
| Global | Primary classification | The event markets itself as a premier Asia bio-industry partnering event and has strong international relevance across biotech, pharma, and regenerative medicine. |
4. Sample Buyer Companies and Websites
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| Takeda Pharmaceutical Company Limited | Pharma buyer / innovation partner | Major global pharma stakeholder; strong fit for partnering, licensing, and research collaboration. | takeda.com | Business Development Director; R&D Director; Strategic Sourcing Manager | Confirmed Speaker Organization |
| Chugai Pharmaceutical Co., Ltd. | Pharma buyer / alliance partner | Relevant for biopharma partnering, clinical development, and innovation scouting. | chugai-pharm.co.jp | Alliance Manager; Head of BD; Procurement Manager | Confirmed Speaker Organization |
| Asahi Kasei Corporation | Industrial / healthcare innovation buyer | Named in organizer leadership; strong fit for biomaterials, healthcare, and life science technology sourcing. | asahi-kasei.com | Innovation Director; Business Development Director; Category Manager | Confirmed Speaker Organization |
| RIKEN | Public research organization | High-value research buyer for scientific instrumentation, data, and collaboration opportunities. | riken.jp | Lab Director; Procurement Officer; Research Manager | Confirmed Government / Procurement Organization |
| Japan Tissue Engineering Co., Ltd. | Regenerative medicine buyer / solution provider | Direct fit for cell therapy, tissue engineering, and advanced medical technologies. | j-tec.co.jp | R&D Director; Regulatory Affairs Lead; Business Development Manager | Confirmed Speaker Organization |
| Meiji Seika Pharma Co., Ltd. | Pharma buyer / manufacturer | Strong fit for ingredients, R&D, manufacturing, and external innovation. | meiji-seika-pharma.co.jp | Procurement Manager; Manufacturing Director; BD Director | Confirmed Speaker Organization |
| Japan Pharmaceutical Manufacturers Association | Industry association / influencer | Important gatekeeper and network hub for pharma industry decision-makers. | jpma.or.jp | Policy Director; Association Executive; Partnerships Lead | Confirmed Speaker Organization |
| University of Tokyo | Academic / research buyer | Major source of biotech research, tech transfer, and startup formation. | u-tokyo.ac.jp | Research Director; Technology Transfer Officer; Procurement Manager | Confirmed Speaker Organization |
| Osaka University | Academic / translational research buyer | Relevant for clinical translation, biotech innovation, and partnership development. | osaka-u.ac.jp | Research Institute Director; Partnerships Director; Lab Procurement Lead | Confirmed Speaker Organization |
| Forum for Innovative Regenerative Medicine (FIRM) | Regenerative medicine network / buyer influencer | Strong ecosystem relevance for cell therapy, tissue engineering, and commercial partnering. | firm.or.jp | Executive Director; Partnerships Manager; Program Lead | Confirmed Speaker Organization |
| Japan Bioindustry Association (JBA) | Industry association / buyer influencer | Central bio-industry membership body; strong network for enterprise and institutional buyers. | jba.or.jp | Executive Director; Membership Lead; Partnerships Director | Confirmed Speaker Organization |
| Yakult Bio-Science Foundation | Research / foundation buyer | Relevant for research funding, collaboration, and scientific programs. | yakult.co.jp | Foundation Director; Research Program Manager; Grants Lead | Confirmed Speaker Organization |
| Japan Association for Techno-innovation in Agriculture, Forestry and Fisheries | Innovation / public-interest organization | Useful for bio-innovation, applied research, and cross-sector collaboration. | jataff.or.jp | Program Director; Innovation Lead; Partnerships Manager | Confirmed Speaker Organization |
| Japan Biological Informatics Consortium | Bioinformatics / data consortium | Relevant for data platforms, bioinformatics tools, and digital transformation in life sciences. | j-bioinformatics.jp | Data Director; Digital Transformation Lead; Partnership Manager | Confirmed Speaker Organization |
5. Job Profiles, Industries and Event Type
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | Chief Procurement Officer / Head of Procurement | Procurement | C-Level / VP | Owns strategic sourcing for lab, clinical, and operational categories. |
| 2 | Director of Business Development / Alliance Management | Business Development | Director / VP | Primary decision-maker for partnering and licensing meetings. |
| 3 | R&D Director / Head of Research | Research & Development | Director / VP | Evaluates technologies, platforms, and external innovation. |
| 4 | Regulatory Affairs Manager / Quality Manager | Regulatory / Quality | Manager / Senior Manager | Validates compliance and vendor acceptability. |
| 5 | Strategic Sourcing Manager | Procurement / Supply Chain | Manager / Senior Manager | Influences vendor shortlisting and commercial negotiations. |
| 6 | Clinical Development Director | Clinical / Medical Affairs | Director | Looks for trial support, endpoints, and partner technologies. |
| 7 | Technology Transfer Officer | Innovation / TTO | Manager / Director | Matches academic research with commercial partners. |
| 8 | Innovation Director / Open Innovation Lead | Corporate Strategy / Innovation | Director / VP | Scans the market for new platforms and collaborative opportunities. |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Pharmaceuticals | Core attendee and sponsor ecosystem for BioJapan. | Licensing, research tools, outsourcing, partnering |
| 2 | Biotechnology | Primary innovation and commercialization sector. | Platform technologies, collaboration, funding |
| 3 | Medical Devices | Important for diagnostics, regenerative and clinical solutions. | Device partnerships, clinical adoption, supply chain |
| 4 | Hospital & Health Care | Relevant for clinical research, regenerative medicine, and health-tech adoption. | Hospital innovation, clinical procurement, digital health |
| 5 | Research | Strong academic and institute participation. | Instrumentation, software, scientific services |
| 6 | Hospitality | Useful for venue services, travel, and meeting support around the event. | Travel, accommodations, event services |
| 7 | Information Technology & Services | Supports health-tech, data, AI, and partnering platforms. | Digital health, lab software, data platforms |
| 8 | Information Technology & Services | AI, data, and informatics are increasingly important in bio-industry workflows. | AI discovery, analytics, workflow automation |
| 9 | Government Administration | Relevant for public research, policy, and innovation funding bodies. | Public-sector partnerships, grants, procurement |
| 10 | Medical Devices | Diagnostic and therapeutic device makers often attend for partnering and market access. | Device commercialization, distribution, OEM |
6. Estimated Attendance
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | Not publicly confirmed for 2026 | Confirmed unavailable | Organizer site does not publish a 2026 attendee count in the provided text | Use historical evidence for planning only |
| Historical attendance | 22,167 | Historical / prior-year evidence | Official 2025 visitor count published by organizer | Includes concurrent events |
| Exhibitor count | Not publicly confirmed in provided text | Unavailable | Official page mentions exhibitor application closure but no count in provided text | Potentially available in prior-year pages or brochure |
| Buyer count | Not publicly confirmed | Unavailable | No official buyer total released in provided text | Buyer-side profile inferred from event format |
| Speaker count | Not publicly confirmed | Unavailable | No official count in provided text | Seminar plans exist, but count not provided |
7. Key Focus Areas and Buyer Engagement
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| Partnering | Identify collaborators, licensors, and co-development partners | Meeting-booking and partnership pipelines | BD tools, partnering platforms, advisory services |
| Biopharma R&D | New discovery, preclinical, and translational capabilities | Target R&D heads and innovation teams | Assays, reagents, CRO support, lab instrumentation |
| Regenerative Medicine | Cell therapy, tissue engineering, and cell processing solutions | Engage therapy developers and manufacturing leads | Bioprocess tools, GMP services, storage, QC systems |
| Digital Health / healthTECH | Data, software, AI, workflow digitization | Target innovation, IT, and clinical operations teams | Software, AI analytics, interoperability, cloud tools |
| Procurement & Sourcing | Approved suppliers with compliance and quality assurance | Capture budget owners and vendor evaluators | Distribution, logistics, equipment, consumables, services |
| Research Collaboration | Access to labs, funding, and scientific expertise | Target universities and public institutes | Instruments, grants support, services, informatics |
Lead Quality Assessment
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | Very High | The event attracts pharma, biotech, academia, public research, and health-tech decision-makers. |
| Decision-maker availability | High | Partnering format increases access to senior commercial, research, and procurement contacts. |
| Data collection potential | High | Strong potential for attendee profiling, lead enrichment, and partner mapping. |
| Apollo targeting potential | Very High | Clear industry clusters, job functions, and seniorities make this highly targetable. |
| Geographic targeting potential | High | Excellent domestic and Asia-Pacific geographic segmentation is possible. |
| Best outreach approach | Partnering-first, research-driven outreach | Lead with collaboration value, then qualify by function, pipeline, and procurement need. |
| Overall lead quality | Very High | One of the strongest B2B lead-generation events in Asia for life sciences and health-tech. |
| Best use case | Buyer list building, account-based outreach, partnership sales, and event data enrichment | Ideal for target account mapping and commercial pipeline development. |
| Limitations / risks | Moderate | Current-year attendee list is not publicly confirmed in the provided source text, so attendee claims must remain conservative. |
Apollo.io Targeting Recommendation
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Pharmaceuticals; Biotechnology; Medical Devices; Hospital & Health Care; Research; Information Technology & Services; Government Administration; Higher Education; Venture Capital & Private Equity; Financial Services | Capture core buyers, influencers, funders, and research institutions |
| Departments | Procurement; Business Development; R&D; Strategy; Clinical; Regulatory; Innovation; Operations; IT | Focus on people who influence buying, partnerships, or adoption |
| Seniority | Manager; Senior Manager; Director; VP; CXO; Head; Owner | Prioritize decision-makers and budget holders |
| Job titles | Chief Procurement Officer; VP Procurement; Director of Procurement; Strategic Sourcing Manager; Business Development Director; Alliance Director; R&D Director; Innovation Director; Regulatory Affairs Director; Technology Transfer Officer | High-fit titles for outreach and attendee profiling |
| Geography | Japan; Greater Tokyo; APAC; South Korea; Taiwan; Singapore; China; United States; United Kingdom; Germany | Match the event’s domestic base and international partnering audience |
| Employee size | 11-50; 51-200; 201-500; 501-1,000; 1,001-5,000; 5,001+ | Covers startup innovators through large enterprise buyers |
| Keywords | biotech, regenerative medicine, cell therapy, drug discovery, partnering, licensing, clinical development, lab automation, digital health, bioinformatics | Refine leads to event-relevant themes |
| Company type | Public company; private company; research institution; university; government-affiliated body; startup; corporate venture unit | Broaden to the full decision-maker ecosystem |
Suggested Apollo Search Logic: (biotech OR pharmaceuticals OR regenerative medicine OR cell therapy OR digital health OR bioinformatics) AND (procurement OR sourcing OR business development OR alliance OR R&D OR innovation OR regulatory) AND (director OR VP OR head OR manager OR C-level). Add geography filters for Japan, APAC, and key global biotech hubs.
Client Fit Review Required
Please share the client website or product/service details. I will review the client offering and identify the highest-fit buyer companies, Apollo industries, seniority levels, departments, and job titles from this event.
Sources & Verification Notes
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| BioJapan official website | Official organizer website | Event name, 2026 dates, venue, positioning, organizer structure, partnering format, and 2025 visitor count | Very High |
| PACIFICO Yokohama official venue reference | Venue source reference | Venue identification and city match | High |
| Official website “Previous Show (2025)” visitor count section | Organizer-published historical evidence | 2025 total visitor count of 22,167 including concurrent events | Very High |
| Official organizer leadership / committee listings | Organizer / association listing | Association and institutional ecosystem connected to the event | High |
| BioJapan official news items on exhibitor application closure | Organizer news update | Confirmed that 2026 exhibitor registration closed on May 29, 2026 | Very High |
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to BioJapan — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds